Besides, another agreement on joint elaboration and manufacturing of innovative ARV-drugs was signed with the Russian company ChemRar. The range of products planned for manufacturing is in conformity with therapeutic regimens and WHO recommendations on ARV therapy.
«The implementation of the two projects by 2019 will allow to fully meet the need of these products by the aid of the domestic manufacturers and to reduce the price of the treatment regimen two times for the Russian patients. The first commercially available drugs will appear in as early as 2017; by 2018 the production will reach its full capacity. Total investment in the projects will be around 4 billion roubles» — said Sergei Chemezov, the CEO of the state corporation Rostec.
«Today the patients undergoing anti-HIV treatment in Russia have to take 6–8 pills every day. Our goal is to produce co-formulated medicines, which can reduce treatment to 2–3 pills per day and significantly increase the patients’commitment to the treatment. Moreover, we are planning to reduce the cost of the treatment course for the patients from current USD1170 to USD650 in a short perspective, which will double the therapy coverage with the same financing», stated Nikolai Semenov, the CEO Nacimbio CEO. «The study we have carried out shows that only in case of the integrated production cycle we can achieve the most competitive price of the product. This measure will provide 80–90% therapy coverage», added Nikolay Semenov.
Nikolai Semenov, Nacimbio CEO and Chawla Chandru Jaswant, the head for the Corporate Strategy & New Ventures of Cipla Ltd., leading ARV drugs production company, signed the agreement on technology transfer for anti-HIV drugs and drugs for viral Hepatitis treatment.
Within the frames of the signed agreement the construction and validation of the manufacturing plant will be finalised in 2017, its products will be commercially available in 2018. The total amount of investments to the project with the company Cipla will exceed 3.3 billion rubles.
«We are really proud to be the partners of Cipla Ltd — a global leader in HIV/AIDS and Hepatitis drugs production», said Nikolay Semenov. «Most of the company’s products have passed the WHO qualification and are shipped to more than 100 countries all over the world, including the supplies within the frames of the international health support programs. Also, the production sites of Cipla are certified in USA, EU, Japan, Great Britan and the medicines are sold in the European and North-American markets».
«Currently there is no technology for fully integrated manufacturing of HIV treatment drugs in Russia. We are aware of responsibility we embrace as a partner," said Chawla Chandru Jaswant. «We are glad that together with Nacimbio we will be able to improve the drug supply for the patients and thus to make our contribution to the fight against this dreadful disease».
Another document signed in the course of the Forum was the agreement with ChemRar which constitutes a part of Nacimbio strategy. The agreement was signed by Nikolai Semenov, the CEO of Nacimbio and Andrei Ivashenko, the Chairman of ChemRar Board of Directors. As a result of Nacimbio and ChemRar’s cooperation a joint venture will be created that will provide for all stages of product’s life cycle: from research and development to production and sales. As early as in 2017 the fully integrated drug production will be launched. The amount of investments in the project with ChemRar will be over 1 billion rubles.
Nikolay Semenov commented on the agreement with ChemRar: «We have been monitoring the dynamic development of this innovative company for a long time and it is perfectly clear now that ChemRar is one of the leading companies. Very soon it will be able to manufacture for commercial realization not only the generics, but also the drugs with the potential of worldwide blockbusters. Their unique findings are extremely valuable for us since our goal is not just to phase-out imports and to reduce the drug prices but also to launch the innovative locally produced drugs to the Russian market «.
«It is pivotal that for the first time the Russian market will embrace innovative antiviral drugs developed by the Russian researchers and produced entirely on the territory of the Russian Federation. These drugs are long-awaited by our patients and we will apply all our efforts to launch production on time and with the expected production volumes», said Andrey Ivashenko.
Also, on the sidelines of the Forum «Nacimbio» has signed the agreement with the Indian investment company «Ishvan Ltd». «Ishvan Ltd» is interested in the development of the drugs’ production on the territory of Russia.
National Immune-biological Company was established as part of Rostec State Corporation in 2013 as the organization managing the holding company formation in the immune-biological products development and production. The holding company aims to ensure the independence of the Russian Federation from foreign medicinal drugs (immune-biological drugs and drugs against infectious diseases, in particular) through the development of its own production and scientific expertise. In particular, the holding’s development strategy envisages producing up to 100% of the national vaccine needs within the National Immunization Schedule at the holding facilities by 2020. To achieve these goals, a number of manufacturing enterprises, including MICROGEN, FORT, Syntez and Metallist will join the holding company National Immune-biological Company.
Cipla is a global pharmaceutical company, which uses innovative technologies in order to meet the everyday needs of all patients — providing the quality drugs at affordable price. For its’ 80-years history, Cipla has become one of the most respected pharmaceutical names in India as well as across more than 100 countries. The company’s portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.
The company offers the biggest in the world range of HIV-treatment drugs approved by the WHO and the US FDA. Cipla produces 16 anti-retroviral products for the first, second and third lines and more than 40 various combinations: fixed dosage «2 in 1», combinations «3 in 1», and other formulations including the liquid formats. Currently the share of Cipla’s anti-AIDS products is 70 — 80%.
Advanced Technologies Center «ChemRar» is a Russian non-state innovative business incubation of hi-tech companies operating in the area of living systems. The key mission of the group of companies ChemRar is to develop and bring to the market the original medicines based on the latest «post-genome» technologies for treating the oncologic and infectious diseases, as well as the central nervous system diseases. The modern production facilities of ChemRar allow carrying out the entire cycle of pre-clinical and clinical development of the new medicines and medicinal formulations starting with identification of the relevant biotargets for the effective screening, synthesis and tests of the new molecule and medicinal formats and ending with the launch of the new products to the market. www.chemrar.ru
Rostec State Corporation is a Russian corporation, created in 2007 to promote development, production and export of high-tech industrial products designed for civil and military use. The corporation comprises 663 organizations, nine of which are currently formed into holding companies in the military-industrial complex and six operate in civilian industries, as well as 32 direct management organizations. Rostec’s portfolio includes such famous brands as AVTOVAZ, KAMAZ, Russian Helicopters, VSMPO-AVISMA Corporation and others. Rostec organizations are located in the territory of 60 subjects of the Russian Federation and supply products to the markets of over 70 countries. Rostec revenues in 2014 amounted to 964.5 billion rubles. The total amount of tax deductions amounted to 147.8 billion rubles.
Source:
http://nacimbio.ru/en/press/news/natsimbio-zapuskaet-kompleksnuyu-programmu-po-proizvodstvu-preparat...
